We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
+22.64%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.33B
AUM Growth
+$30M
(+2.3%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-10.53%
Top 10 Holdings %
Top 10 Hldgs %
81.33%
Holding
38
New
1
Increased
4
Reduced
2
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oric Pharmaceuticals
ORIC
|
+$12.9M |
| 2 |
Trevi Therapeutics
TRVI
|
+$11.5M |
| 3 |
Celcuity
CELC
|
+$11.4M |
| 4 |
OMDA
Omada Health Inc
OMDA
|
+$6.3M |
| 5 |
ZBIO
Zenas BioPharma
ZBIO
|
+$1.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TEM
Tempus AI
TEM
|
+$126M |
| 2 |
VRNA
Verona Pharma
VRNA
|
+$31.5M |
| 3 |
RGLS
Regulus Therapeutics
RGLS
|
+$11.3M |
| 4 |
DM
Desktop Metal, Inc.
DM
|
+$7.07M |
| 5 |
BuzzFeed
BZFD
|
+$5.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.51% |
| 2 | Consumer Staples | 8.49% |
| 3 | Industrials | 0.01% |
| 4 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACLX
1
DELISTED
Arcellx
ACLX
| $247M | 18.56% |
3,745,262
| – | – |
|
|
VRNA
2
DELISTED
Verona Pharma
VRNA
| $214M | 16.11% |
2,263,138
-425,427
| -16% | -$31.5M |
|
3
Rhythm Pharmaceuticals
RYTM
$7.31B
| $184M | 13.84% |
2,909,956
| – | – |
|
4
Coursera
COUR
$1.59B
| $113M | 8.49% |
12,867,769
| – | – |
|
5
CRISPR Therapeutics
CRSP
$4.71B
| $77.2M | 5.81% |
1,587,854
| – | – |
|
|
6
Trevi Therapeutics
TRVI
$2.71B
| $72.3M | 5.44% |
13,222,228
+1,851,852
| +16% | +$11.5M |
|
7
Savara
SVRA
$1.13B
| $55.8M | 4.2% |
24,471,264
| – | – |
|
|
8
Oric Pharmaceuticals
ORIC
$1.11B
| $41.8M | 3.15% |
4,118,621
+1,923,076
| +88% | +$12.9M |
|
|
MBX
9
MBX Biosciences
MBX
$2.99B
| $41.2M | 3.1% |
3,614,486
| – | – |
|
10
Monte Rosa Therapeutics
GLUE
$2.07B
| $34.7M | 2.61% |
7,692,298
| – | – |
|
11
Aurinia Pharmaceuticals
AUPH
$2.05B
| $33.6M | 2.53% |
3,969,834
| – | – |
|
|
12
Celcuity
CELC
$4.31B
| $30.6M | 2.31% |
2,294,261
+1,044,260
| +84% | +$11.4M |
|
|
ZBIO
13
Zenas BioPharma
ZBIO
$1.86B
| $26.5M | 1.99% |
2,733,719
+119,771
| +5% | +$1.17M |
|
14
Gossamer Bio
GOSS
$83.2M
| $22.3M | 1.68% |
18,093,034
| – | – |
|
|
NEUE
15
DELISTED
NeueHealth
NEUE
| $18.8M | 1.42% |
2,726,917
| – | – |
|
16
Phathom Pharmaceuticals
PHAT
$873M
| $18.8M | 1.42% |
1,960,169
| – | – |
|
17
Korro Bio
KRRO
$177M
| $13.6M | 1.03% |
1,090,793
| – | – |
|
18
Champions Oncology
CSBR
$85.1M
| $12.6M | 0.95% |
1,713,720
| – | – |
|
19
CVRx
CVRX
$130M
| $11.9M | 0.9% |
2,026,083
| – | – |
|
20
Black Diamond Therapeutics
BDTX
$103M
| $11M | 0.83% |
4,448,757
| – | – |
|
|
INZY
21
DELISTED
Inozyme Pharma
INZY
| $9.75M | 0.73% |
2,437,689
| – | – |
|
22
Senti Biosciences Holdings
SNTI
$13.6M
| $7.97M | 0.6% |
3,775,615
| – | – |
|
|
OMDA
23
Omada Health Inc
OMDA
$1.41B
| $6.66M | 0.5% |
+364,115
| New | +$6.3M |
|
24
Nkarta
NKTX
$186M
| $5.92M | 0.45% |
3,568,781
| – | – |
|
|
IVA
25
Inventiva
IVA
$1.09B
| $4.67M | 0.35% |
1,462,586
| – | – |
|
Similar funds
NM
EK
SLF
PCA
CCIA
SRIM
SW
CGH
NEA Management Company's Q2 2025 Portfolio in Review
As of Q2 2025, NEA Management Company held 38 positions worth $1.33B, up 2.3% from $1.3B the previous quarter. Its ten largest holdings account for 81% of the portfolio.
NEA Management Company withdrew a net $140M in Q2 2025, closing 6 positions and reducing 2 holdings. Its most notable exit was Tempus AI, an estimated $126M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Industrials.
Against the trend, NEA Management Company opened a new position in Omada Health Inc worth $6.66M.
- NEA Management Company's largest Q2 2025 buy was Omada Health Inc: 364,115 shares worth $6.66M.
- NEA Management Company added most to Oric Pharmaceuticals in Q2 2025, an estimated $12.9M increase.
- NEA Management Company's biggest Q2 2025 reduction was Verona Pharma, cutting an estimated $31.5M.
- NEA Management Company fully exited Tempus AI in Q2 2025, selling an estimated $126M.
- NEA Management Company's ten largest holdings make up 81% of its $1.33B portfolio in Q2 2025.
- NEA Management Company opened 1 new position and closed 6 in Q2 2025.
- NEA Management Company's portfolio value rose 2.3% quarter-over-quarter to $1.33B.
Based on NEA Management Company's 13F filing for Q2 2025, filed 14 Aug 2025.